2
Clinical Trials associated with BCMA-TGFβ CAR-T cells(Medical College of Wisconsin) / Not yet recruitingPhase 1IIT Phase I Study of BCMA-TGF-BETA Insensitive Armored CAR T Cells in Patients with Relapsed And/or Refractory Multiple Myeloma
This is a phase I, interventional, single-arm, open-label, dose-finding treatment study designed to evaluate the safety and efficacy of interleukin-7(IL-7) / interleukin-15 (IL-15) manufactured CAR T cells in adult patients with relapsed and/or refractory myeloma that have failed prior therapies.
To investigate the effectiveness and safety of up-front consolidation with BCMA-targeted CAR T-cell for newly diagnosed multiple myeloma
Start Date15 May 2021 |
Sponsor / Collaborator- |
100 Clinical Results associated with BCMA-TGFβ CAR-T cells(Medical College of Wisconsin)
100 Translational Medicine associated with BCMA-TGFβ CAR-T cells(Medical College of Wisconsin)
100 Patents (Medical) associated with BCMA-TGFβ CAR-T cells(Medical College of Wisconsin)
100 Deals associated with BCMA-TGFβ CAR-T cells(Medical College of Wisconsin)